Amphastar Pharma (AMPH) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Jefferies
May 9, 2017 9:50 AM EDTJefferies lowered its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $20.00 (from $21.00) while maintaining a Buy rating. 1Q EPS of $0.09 was ahead of consensus estimates on lower spending.
Management reported that the FDA recently completed pre-approval inspections for 5 of the 6 ANDAs... More
